Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things, hear about IP waivers for coronavirus vaccines; launch records for Pfizer’s COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 May 2021, including: possible intellectual property waivers for coronavirus vaccines; launch records for Pfizer Inc.’s COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "US COVID Vaccine Patent Waiver Is Big, Symbolic Blow For Pharma, But The Fight Is Just Beginning" - Scrip, 5 May, 2021.)

(Also see "Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected" - Scrip, 4 May, 2021.)

(Also see "Your Annual COVID-19 Vaccine Booster Could Be A Pill Or A Spray" - Scrip, 30 Apr, 2021.)

(Also see "With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?" - Scrip, 3 May, 2021.)

(Also see "The 2021 Worldwide Pharma And Biotech R&D Scene" - Scrip, 5 May, 2021.)

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel